ASCO Clinical Notice Against Fenbendazole and Ivermectin: What Patients Need to Know (May 2026)
In May 2026, the American Society of Clinical Oncology issued a formal clinical notice recommending against the use of fenbendazole and ivermectin as cancer treatments. We break down what the notice says — and what the emerging observational data shows.
By Sanare Lab · July 14, 2026 · 6 min read
As of mid-2026, few topics in the repurposed-drug space are as consequential as the American Society of Clinical Oncology's formal position on fenbendazole and ivermectin. When the largest body of practicing oncologists in the world issues a clinical notice, patients and clinicians alike take notice. Yet the same year has produced observational data and a National Cancer Institute investigation that keep the scientific question open. This brief separates the institutional message from the evolving evidence so you can have a better-informed conversation with your own care team.
Table of Contents
What the ASCO Notice Said
In May 2026, the American Society of Clinical Oncology (ASCO) — the world's leading professional organization for physicians and researchers who treat cancer — published a formal Clinical Notice recommending against the use of fenbendazole and ivermectin as cancer treatments. The notice was direct: at this time, ASCO does not consider either compound to be a safe or effective cancer therapy, and it advised patients not to substitute these agents for evidence-based oncology care.
ASCO grounded its position in three main concerns. First, there are no completed, peer-reviewed, randomized controlled trials (RCTs) demonstrating that fenbendazole or ivermectin cures or controls cancer in humans. RCTs are the gold standard because they isolate a drug's true effect from placebo, natural disease fluctuation, and the many confounders that plague anecdotal reports. Second, ASCO warned about potential toxicity — particularly liver injury with high-dose or prolonged fenbendazole use, and neurological effects with supratherapeutic ivermectin dosing. Third, and most importantly from a clinical standpoint, ASCO emphasized the risk of delaying or abandoning proven treatments. When a patient replaces a therapy with a documented survival benefit (surgery, chemotherapy, immunotherapy, radiation) with an unproven compound, the opportunity cost can be measured in months of disease progression.
It is worth reading the notice in the spirit it was written. ASCO is not claiming these molecules are biologically inert — the preclinical literature clearly shows anticancer activity in cell and animal models. Rather, the organization is drawing a bright line between laboratory promise and clinical proof, and reminding patients that the burden of proof for a cancer therapy is deliberately high.
Why Patients Continue Using These Compounds
Despite the absence of RCT evidence, interest in fenbendazole and ivermectin as repurposed cancer agents has grown rapidly since roughly 2019, when the Joe Tippens story went viral. Several forces drive this phenomenon. Both drugs are inexpensive, widely available, and off-patent — meaning no pharmaceutical company has a financial incentive to fund the expensive trials that would formally establish (or refute) efficacy. This creates a genuine "orphaned hypothesis" problem: the science may be worth testing, but the market will not test it.
Patients are also motivated by mechanism. Both compounds have plausible, published anticancer mechanisms — microtubule disruption, interference with cellular energy metabolism, and modulation of signaling pathways such as Wnt/β-catenin and STAT3. When patients read this preclinical literature, the leap to "it might help me" is understandable, especially for those with advanced disease and limited options.
Finally, a steady stream of anecdotal remission reports circulates online. These stories are emotionally compelling and often sincere, but they cannot distinguish the effect of the repurposed drug from concurrent standard treatment, spontaneous remission, or misdiagnosis. This is precisely the gap that observational and, ultimately, randomized research must fill.
The Observational Evidence: AR 2026 Study
The ASCO notice arrived in the same year as one of the largest data sets yet compiled on repurposed antiparasitics in oncology. A prospective observational study published in Anticancer Research (Vol. 46, No. 6, 2026) followed 197 cancer patients using a compounded ivermectin + mebendazole regimen and reported an 84.4% clinical benefit ratio (CBR), with 32.8% of patients achieving no evidence of disease (NED) at follow-up.
These numbers are striking, and they explain why interest persists. But it is essential to read them the way ASCO does. An observational study has no control group: every patient received the intervention, so there is no comparison arm to reveal what would have happened without it. Outcomes were partly self-reported, follow-up was incomplete (122 of 197 patients completed six months), and patients who enroll in such programs are self-selected — often highly engaged, frequently receiving conventional treatment simultaneously. All of these factors can inflate apparent benefit. The AR 2026 study is genuinely hypothesis-generating, but it is not, and its own authors do not claim it to be, proof of efficacy.
Balanced Perspective: Risks and Ongoing Research
The honest picture in 2026 is one of tension between institutional caution and scientific curiosity. On one side, ASCO's clinical notice reflects the mainstream oncology consensus: unproven, potentially toxic, and dangerous if it displaces effective care. On the other, the research establishment is not ignoring the signal. In February 2026, the National Cancer Institute (NCI) announced it had begun preclinical laboratory studies of ivermectin as a potential anticancer agent — a meaningful acknowledgment that the hypothesis deserves rigorous testing.
Context also matters for interpreting anecdote. A widely circulated 2025 case series by Dr. William Makis was retracted in January 2026, underscoring how fragile uncontrolled clinical claims can be. Retraction is the scientific system working as intended — but it is also a caution against building personal treatment decisions on individual reports.
The practical takeaway for patients is not "these drugs don't work" nor "these drugs work." It is that the evidence remains immature, the risks are real, and the correct venue for these compounds is a well-designed clinical trial — not self-treatment. If you are considering fenbendazole or ivermectin, the single most important step is an open, non-judgmental conversation with your treating oncologist about your specific diagnosis, current therapy, and goals of care.
Frequently Asked Questions
Did ASCO ban fenbendazole and ivermectin?
No. ASCO is a professional society, not a regulator, and cannot ban a drug. Its May 2026 Clinical Notice is a formal recommendation against using these compounds as cancer treatments, based on the current lack of randomized trial evidence and concerns about toxicity and treatment delay.
If there is an 84% benefit study, why is ASCO against these drugs?
The 84.4% figure comes from an observational study with no control group, incomplete follow-up, and self-reported data. Without a comparison arm, it cannot show that the drugs themselves caused the outcomes. ASCO's standard for endorsing a therapy is randomized controlled trial evidence, which does not yet exist for these compounds.
Is the NCI studying ivermectin because it works?
The NCI began preclinical (laboratory and animal) studies in February 2026 to evaluate whether ivermectin has anticancer activity worth pursuing. Preclinical investigation is an early step and does not indicate proven efficacy in humans — many compounds that look promising in the lab fail in clinical trials.
Can I take these drugs alongside my standard treatment?
Only under the supervision of your oncologist. Both compounds can interact with other medications and carry toxicity risks. The greatest danger is using them as a replacement for proven therapy. Discuss any supplement or repurposed drug with your care team before starting.
What happened to the Makis case series?
A 2025 case series by Dr. William Makis reporting remissions was retracted in January 2026. Retractions reflect problems identified in the methodology or reporting and are a reminder that uncontrolled case reports are not reliable evidence of efficacy.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested
180 capsules — higher-dose option
120 capsules — with Black Pepper for absorption
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- American Society of Clinical Oncology. "Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment." ASCO Connection, May 2026. Link
- Prospective observational cohort of ivermectin + mebendazole. Anticancer Research, Vol. 46, No. 6, 2026. Link (PubMed 42203321).
- STAT News. "The National Cancer Institute is studying ivermectin as a cancer treatment." February 10, 2026. Link
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.